Group 1 - The company Yabao Chemical (300261) will disclose shareholder data as of December 31, 2025, in its annual report for that year [1]

证券代码：300261 证券简称：雅本化学 公告编号：2026-001 雅本化学股份有限公司 关于为子公司提供担保及子公司为公司提供担保 的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》。为满足子公 司的经营发展需要，公司同意为全资子公司雅本（绍兴）药业有限公司（以下 简称"绍兴雅本"）办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子公司提供担保及子公司互相 担保的公告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一 次临时股东大会审议通过了上述议案。 2025 年 10 月 27 日，公司第六届董事会第七次会议审议通过了《关于增加 2025 年度担保额度及担保对象的议案》，公司同意为全资子公司上海朴颐化学 科技有限公司（以下简称 ...

Core Viewpoint - The business cooperation between Yabonn Chemical and Fumase is currently proceeding normally, and there are no cancellations of orders reported as of now [1] Group 1: Company Operations - Yabonn Chemical confirmed that its collaboration with Fumase is ongoing and functioning as expected [1] - The company stated that the current situation does not meet the criteria for information disclosure, but it will comply with legal requirements for disclosure if necessary [1]

Group 1 - The core point of the news is that Yabao Chemical experienced a decline in stock price and trading volume on December 29, with a net financing buy of -346.42 million yuan, indicating a low level of investor confidence [1] - As of December 29, the total margin balance for Yabao Chemical was 233 million yuan, accounting for 3.59% of its market capitalization, which is below the 40th percentile level over the past year, indicating a low financing level [1] - The company reported a revenue of 996 million yuan for the period from January to September 2025, representing a year-on-year growth of 6%, while the net profit attributable to shareholders was -6.92 million yuan, showing a significant year-on-year increase of 87.81% [2] Group 2 - Yabao Chemical has distributed a total of 478 million yuan in dividends since its A-share listing, with 95.9 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders for Yabao Chemical was 53,100, a decrease of 1.43% from the previous period, while the average circulating shares per person increased by 1.45% to 17,743 shares [2] - Among the top ten circulating shareholders, the Southern CSI 1000 ETF is the seventh largest shareholder with 6.1681 million shares, marking its entry as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten list [3]

Core Viewpoint - Yabao Chemical announced on an interactive platform that as of December 20, 2025, the total number of shareholders will be 53,136 [2] Summary by Category - Company Information - Yabao Chemical has confirmed that the total number of shareholders is projected to reach 53,136 by December 20, 2025 [2] - Industry Context - The announcement reflects the company's ongoing engagement with investors and transparency regarding shareholder growth [2]

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor of NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4][6]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with no known adverse reactions and the highest conversion efficiency [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, making NMN supplements, which can provide up to 300 times the dietary intake, more effective for achieving beneficial doses [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][11]. - Leading companies are innovating in full enzymatic synthesis and patenting technologies to create competitive advantages [12]. Market Trends and Applications - NMN is primarily used in health supplements and cosmetics, with potential expansion into pet nutrition, medical health, and agricultural technology [24][28]. - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by regulatory changes and new applications [28]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60%-70% of market share [35]. Certification and Compliance - The "blue hat" certification for health supplements in China represents the highest standard for NMN products, with strict approval processes impacting market dynamics [37]. Future Prospects - The NMN industry is poised for growth, with increasing demand driven by an aging population and younger consumers seeking anti-aging solutions [19][21]. - Technological advancements in synthesis, quality control, and delivery methods are expected to enhance market growth and product efficacy [21][22]. Challenges - The NMN industry faces challenges such as regulatory hurdles, market education, and the need for scientific validation to support claims [61][63].

证券代码：300261 证券简称：雅本化学 公告编号：2025-084 雅本化学股份有限公司 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其 | 占公 | 情况 | | 情况 | | | 股东名 | 持股数量 | 持股 | 本次质押前 | 本次质押后 | 所持 | 司总 | 已质押股 | 占已 | 未质押股 | 占未 | | | | 比例 | 质押股份数 | 质押股份数 | 股份 | | | 质押 | | 质押 | | 称 | （股） | (%) | 量 | 量 | 比例 | 股本 | 份限售和 | 股份 | 份限售和 | 股份 | | | | | | | (%) | 比例 | 冻结数量 | 比例 | 冻结数量 | 比例 | | | | | | | | | （股） | (%) | （股） | (%) | | 宁波雅 本控股 | | | | | | | | | | | | 有限公 | 257,729,839 | 26.75 ...

一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》。为满足子公 司的经营发展需要，公司同意为全资子公司上海雅本化学有限公司（以下简称 "上海雅本"）、南通雅本化学有限公司（以下简称"南通雅本"）、江苏建 农植物保护有限公司（以下简称"建农植保"）办理银行授信等业务提供担保。 具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子 公司提供担保及子公司互相担保的公告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临时股东大会审议通过了上述议案。 2025 年 6 月 16 日，公司第六届董事会第四次（临时）会议和第六届监事 会第四次（临时）会议审议通过了《关于全资子公司向银行申请项目贷款并由 公司提供担保的议案》，公司同意为南通雅本申请银行项目贷款提供担保，担 保方式为连带责任保证担保，额度不超过人民币 2,500 万元，借款期限不超过 36 个月，主要用于支付项目建设 ...

证券日报网讯 12月19日晚间，雅本化学发布公告称，公司2025年第四次临时股东会审议通过《关于增 加2025年度担保额度及担保对象的议案》。 （文章来源：证券日报） ...

一、会议召开和出席情况 雅本化学股份有限公司（以下简称"公司"）2025 年第四次临时股东会（以 下简称"股东会"）现场会议于 2025 年 12 月 19 日下午 14:30 在上海市浦东新 区新环南路 289 号二楼会议室召开；同时使用深圳证券交易所交易系统网络投票 于 2025 年 12 月 19 日交易时间接受网络投票，即 9:15-9:25，9:30-11:30 和 13:00-15:00；使用深圳证券交易所互联网投票系统于 2025 年 12 月 19 日上午 9:15 至下午 15:00 期间接受网络投票。 出席本次股东会的股东及股东的委托代理人共计 355 人，代表有表决权的股 份数为 268,415,419 股，占公司股份总数的 27.8639％。其中，参加现场会议的股 东及股东代表 3 人，代表股份 258,760,141 股，占公司股份总数的 26.8616％；参 加网络投票的股东及股东代表 352 人，代表股份 9,655,278 股，占公司股份总数 的 1.0023％。 证券代码：300261 证券简称：雅本化学 公告编号：2025-082 雅本化学股份有限公司 2025 年第四次临 ...